uploads///Graph

What Are Analysts’ Recommendations for Mylan and Its Peers?

By

Dec. 4 2020, Updated 10:53 a.m. ET

Analysts’ recommendations

Among the 24 brokerage companies surveyed by Bloomberg for Mylan (MYL), 59.1% gave it “buy” ratings, and 40.9% gave it “hold” ratings. No analysts rated Mylan as a “sell.”

The consensus 12-month target price for Mylan is ~$58.08, which represents a rise of 19.9% from the stock’s price of $48.46 on August 12, 2016. Mylan is expected to benefit from the successful launch of its new drugs across multiple geographies. The company’s additions of Meda and Renaissance Acquisition Holdings have further added to its distribution capabilities, enabling it to benefit from an integrated approach to pharmaceutical sales.

If Mylan manages to reach its price target, its shares could jump, along with the share price of the SPDR S&P 500 ETF (SPY). Mylan makes up about 0.12% of SPY’s total portfolio holdings.

Article continues below advertisement

Peer comparison

Based on a Bloomberg survey of 32 brokerages, Teva Pharmaceuticals (TEVA) received “buy” recommendations from 74.2% of analysts and “hold” recommendations from 25.8% of analysts. The consensus 12-month target price for Teva Pharmaceuticals is ~$69.74, which represents a rise of 29.5% from the stock’s price of $53.86 as of August 12, 2016.

Among the 17 brokerages surveyed by Bloomberg for Akorn (AKRX), 62.5% gave it “buy” ratings, and 37.5% gave it “hold” ratings. No analysts rated Akorn as a “sell.” The consensus 12-month target price for Akorn is ~$36.27, which represents a rise of 18.0% from the stock’s price of $30.73 as of August 12.

Among the 27 brokerages surveyed by Bloomberg for Pfizer (PFE), 57.7% gave it “buy” ratings, and 42.3% gave it “hold” ratings. No analysts rated Pfizer as a “sell.” The consensus 12-month target price for Pfizer is ~$39.68, which represents a rise of 13.4% from the stock’s price of $34.98 as of August 12.

In the next article, we’ll analyze Mylan’s 2016 revenue guidance.

Advertisement

More From Market Realist

    • CONNECT with Market Realist
    • Link to Facebook
    • Link to Twitter
    • Link to Instagram
    • Link to Email Subscribe
    Market Realist Logo
    Do Not Sell My Personal Information

    © Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.